How did Abbott's revenue cost control improve in 2024?

Abbott Laboratories demonstrated improved revenue cost control in 2024, as evidenced by key financial metrics:

1. Revenue Growth: Abbott's total revenue grew by 0.05% to $41.95 billion by the end of 2024. This steady increase reflects effective cost management and market expansion.

2. Gross Margin: The company maintained a robust gross margin of 55.41%, indicating efficient control over production costs relative to sales. This stable gross margin is a testament to Abbott's strong cost management practices.

ABT Gross Profit Margin, Operating Profit Margin

3. Operating Margin: Abbott's operating margin stood at 15.76%, which, while lower than the gross margin, is still indicative of effective cost management within the operating expenses. A strong operating margin suggests that Abbott is managing its day-to-day expenses well.
4. Net Margin: With a net margin of 31.95%, Abbott shows strong profitability, which is a direct result of effective cost control measures. A high net margin indicates that the company is retaining a significant portion of its revenue after covering all expenses.

ABT Net Profit Margin YoY, Net Profit Margin

In conclusion, Abbott Laboratories' revenue cost control improved in 2024, as reflected by its financial metrics such as revenue growth, gross margin, operating margin, and net margin. The company's ability to manage costs effectively, coupled with strategic market positioning, has contributed to its solid financial performance.